carboplatin,pemetrexed,durvalumab,paclitaxel,cisplatin,gemcitabine,pembrolizumab
astrazeneca,merck
['aegean', 'kn-671', '$mrk', '$azn']
after $azn reported aegean at #aacr23 here come nejm / #asco23 kn-671 data $mrk has taken to the fda (16 oct pdufa date): 24mth efs 62.4% vs 40.6% (hr=0.58; p&lt;0.001). 
Once had a blue tick. Journalist at Evaluate Vantage. Interested in: oncology, immunology. Not interested in: what stock you bought today.